.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK01_Dapagliflozin.Dapagliflozin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK01_Dapagliflozin.Dapagliflozin| name: | Dapagliflozin | |
| ATC code: | A10BK01 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 118 | L |
| clearance: | 9.2 | L/h |
| other parameters in model implementation | ||
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus. It lowers blood glucose by promoting urinary glucose excretion and has also been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.
Pharmacokinetic parameters reported for healthy adult volunteers (both male and female) after single oral dose under fasting conditions.
Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. Drugs 79(10) 1135–1146. DOI:10.1007/s40265-019-01148-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31236801
Tirucherai, GS, et al., & Boulton, DW (2016). Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. Diabetes, obesity & metabolism 18(7) 678–684. DOI:10.1111/dom.12638 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27291448
Naagaard, MD, et al., & Boulton, DW (2022). Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. British journal of clinical pharmacology 88(4) 1942–1946. DOI:10.1111/bcp.15117 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34687551